AC
SPRY icon

Apogem Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Apogem Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,793
Closed -$73K – 106
2022
Q3 		$73K Sell
13,793
-12,087
-47% -$59.6K 0.07% 134
2022
Q2 		$110K Buy
25,880
+1,911
+8% +$6.66K 0.1% 145
2022
Q1 		$84K Buy
+23,969
New +$104K 0.06% 167

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Apogem Capital's SPRY Position: Q4 2022 in Review

Apogem Capital sold out of ARS Pharmaceuticals (SPRY) in Q4 2022, closing a stake of 13,793 shares — an estimated $73K sold.

Apogem Capital first reported a position in SPRY in Q1 2022 and held it in 3 quarters. The position peaked at $110K in Q2 2022. 73 funds tracked by Wall St. Rank hold SPRY as of Q4 2022.

  • Apogem Capital reported no remaining ARS Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Apogem Capital sold 13,793 ARS Pharmaceuticals shares in Q4 2022, an estimated $73K.
  • Apogem Capital first reported a position in ARS Pharmaceuticals in Q1 2022 and held it in 3 quarters.
  • Apogem Capital's ARS Pharmaceuticals position peaked at $110K in Q2 2022.
  • 73 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.